Table 6

Correlation analysis between irAEs and survival outcomes

Survival outcomes	Variable	Kaplan–Meier analysis			Cox multivariate regression analysis
Survival outcomes	Variable	HR	95% CI	P	HR	95% CI	P
Progression-free survival	Gender	0.66	0.38–1.13	0.16
	Age	0.80	0.49–1.29	0.34
	ECOG PS	0.80	0.41–1.58	0.49
	BMI	0.59	0.36–0.96	0.030*	0.67	0.40–1.13	0.1371
	Distant metastasis	0.82	0.49–1.36	0.42
	Treatment lines	1.05	0.58–1.91	0.86
	irAEs	2.02	1.25–3.26	0.0038**	2.18	1.22–3.90	0.0087**
Overall survival	Gender	0.78	0.41–1.46	0.46
	Age	0.86	0.51–1.44	0.56
	ECOG PS	1.04	0.51–2.09	0.92
	BMI	0.91	0.54–1.54	0.73
	Distant metastasis	0.69	0.40–1.19	0.16
	Treatment lines	0.97	0.53–1.79	0.86
	irAEs	1.84	1.09–3.09	0.024*

*P < 0.05; **P < 0.01. irAEs, immune-related adverse events; ECOG PS, Eastern Cooperative Oncology Group performance status.